Immutep Limited - ADR
NASDAQ:IMMP
Market Cap (Intraday) | 182.24M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $2.00 |
50-Day MA | $2.04 |
200-Day MA | $2.12 |
Immutep Limited - ADR Stock, NASDAQ:IMMP
Level 33, Australia Square, 264 George Street, Sydney, New South Wales (NSW) 2000
Australia
Phone: +61.2.8315.7003
Number of Employees:
Description
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK�781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.